vimarsana.com

ஸ்பொந்தய்லோஆறத்ரிடிச் ஆராய்ச்சி கூட்டமைப்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Oral JAK 1 Inhibitor Eases Spine Inflammation in Ankylosing Spondylitis

European Commission Approves AbbVie s RINVOQ™ (Upadacitinib) for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis

European Commission Approves AbbVie s RINVOQ™ (Upadacitinib) for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis - RINVOQ (15 mg, once daily) is the first oral, once-daily, selective and reversible JAK inhibitor approved for three adult rheumatic indications in the European Union: rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis[1,2] - Approval is supported by data from three pivotal clinical studies in psoriatic arthritis and ankylosing spondylitis where RINVOQ met all primary and met key secondary endpoints with a safety profile consistent with that seen in rheumatoid arthritis[2-6] - Approvals underscore AbbVie s longstanding commitment to deliver innovative medicines for people living with rheumatic diseases

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.